NeuroOne Medical Technologies Corp. (NMTC) Long-Term Liabilities to Equity

The competent management of NeuroOne Medical Technologies (NMTC) is successfully navigating FDA regulatory cycles, expanding its presence across US neurocenters. This GURU.Markets chart of long-term debt-to-equity demonstrates financial stability, where the 0.02 mark captures this metric. NeuroOne Medical Technologies (NMTC) relies on the production of systems to combat epilepsy and Parkinson's disease, maintaining leadership within the specialized medical sector.

NeuroOne Medical Technologies (NMTC) is developing high-tech production of precision neurosurgical electrodes. This long-term debt-to-equity ratio compares liabilities with maturities exceeding one year against the issuer's own funds. The metric determines the extent to which innovation development depends on external borrowings. This chart reflects the balance between financial leverage and bankruptcy risk. For the investor, this serves as an indicator of business model stability during product scaling.